Annexon Management

Management criteria checks 4/4

Annexon's CEO is Doug Love, appointed in Dec 2014, has a tenure of 9.92 years. total yearly compensation is $2.45M, comprised of 24.2% salary and 75.8% bonuses, including company stock and options. directly owns 0.28% of the company’s shares, worth $2.16M. The average tenure of the management team and the board of directors is 2.5 years and 6.1 years respectively.

Key information

Doug Love

Chief executive officer

US$2.5m

Total compensation

CEO salary percentage24.2%
CEO tenure9.9yrs
CEO ownership0.3%
Management average tenure2.5yrs
Board average tenure6.1yrs

Recent management updates

Recent updates

We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely

Sep 27
We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely

Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS

Aug 17

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Jun 04

Annexon: Unforced Error Sullies Prospects

Apr 03

Here's Why We're Watching Annexon's (NASDAQ:ANNX) Cash Burn Situation

Nov 10
Here's Why We're Watching Annexon's (NASDAQ:ANNX) Cash Burn Situation

Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Jul 25
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Apr 11
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Are Investors Undervaluing Annexon, Inc. (NASDAQ:ANNX) By 25%?

Feb 14
Are Investors Undervaluing Annexon, Inc. (NASDAQ:ANNX) By 25%?

We Think Annexon (NASDAQ:ANNX) Needs To Drive Business Growth Carefully

Dec 28
We Think Annexon (NASDAQ:ANNX) Needs To Drive Business Growth Carefully

Annexon started as a buy at Jefferies on market potential of candidates, data catalysts

Sep 16

Annexon: A First Take

Aug 21

Annexon Biosciences GAAP EPS of -$0.96 misses by $0.02

Aug 08

Annexon to raise $130M in stock and warrant offering

Jul 08

We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate

Apr 16
We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Jan 01
Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Sep 08
Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

May 22
We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

Feb 06
We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

Dosing underway in Annexon's Phase 2/3 study of monoclonal antibody in Guillain-Barré Syndrome

Dec 21

Annexon Biosciences EPS misses by $0.43

Nov 16

CEO Compensation Analysis

How has Doug Love's remuneration changed compared to Annexon's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$115m

Mar 31 2024n/an/a

-US$121m

Dec 31 2023US$2mUS$593k

-US$134m

Sep 30 2023n/an/a

-US$141m

Jun 30 2023n/an/a

-US$143m

Mar 31 2023n/an/a

-US$145m

Dec 31 2022US$4mUS$569k

-US$142m

Sep 30 2022n/an/a

-US$145m

Jun 30 2022n/an/a

-US$145m

Mar 31 2022n/an/a

-US$140m

Dec 31 2021US$8mUS$534k

-US$130m

Sep 30 2021n/an/a

-US$116m

Jun 30 2021n/an/a

-US$103m

Mar 31 2021n/an/a

-US$84m

Dec 31 2020US$5mUS$446k

-US$70m

Sep 30 2020n/an/a

-US$56m

Jun 30 2020n/an/a

-US$45m

Mar 31 2020n/an/a

-US$42m

Dec 31 2019US$3mUS$396k

-US$38m

Sep 30 2019n/an/a

-US$34m

Jun 30 2019n/an/a

-US$28m

Mar 31 2019n/an/a

-US$23m

Dec 31 2018US$518kUS$379k

-US$18m

Compensation vs Market: Doug's total compensation ($USD2.45M) is about average for companies of similar size in the US market ($USD3.24M).

Compensation vs Earnings: Doug's compensation has been consistent with company performance over the past year.


CEO

Doug Love (56 yo)

9.9yrs

Tenure

US$2,453,184

Compensation

Mr. Douglas Love, Esq., J.D, also known as Doug, has been the President, Director and Chief Executive Officer of Annexon Inc. since December 2014. He has extensive business and legal leadership experience...


Leadership Team

NamePositionTenureCompensationOwnership
Douglas Love
CEO, President & Director9.9yrsUS$2.45m0.28%
$ 2.2m
Dean Artis
Chief Scientific Officer & Executive VP1.8yrsUS$1.83m0.048%
$ 366.4k
Ted Yednock
Executive VP3.1yrsUS$1.14m0.068%
$ 519.6k
Jennifer Lew
Executive VP5.4yrsUS$1.44m0.026%
$ 200.4k
Michael Overdorf
Executive VP & Chief Business Officer4.3yrsUS$1.40m0.034%
$ 259.7k
Henk-Andre Kroon
Senior Vice President of Translational Medicineno datano datano data
Jamie Dananberg
Executive VP & Chief Medical Officer1.3yrsno datano data
Shikhar Agarwal
Senior VP & Head of Commercialless than a yearno datano data
Sunil Mehta
Senior VP of Medical Affairsless than a yearno datano data

2.5yrs

Average Tenure

59.5yo

Average Age

Experienced Management: ANNX's management team is considered experienced (2.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Douglas Love
CEO, President & Director9.9yrsUS$2.45m0.28%
$ 2.2m
Ted Yednock
Executive VPless than a yearUS$1.14m0.068%
$ 519.6k
Muneer Satter
Independent Director9.9yrsUS$103.93k0.76%
$ 5.9m
Thomas Wiggans
Independent Chairman7.8yrsUS$132.43k0.00026%
$ 2.0k
Jung Choi
Independent Director4.4yrsUS$100.93k0%
$ 0
William Waddill
Independent Director3.3yrsUS$103.43k0%
$ 0
Thomas Maniatis
Member of Scientific Advisory Boardno datano datano data
David Holtzman
Member of Scientific Advisory Boardno datano datano data
Stephen Hauser
Member of Scientific Advisory Boardno datano datano data
Jeffrey Goldberg
Member of Scientific Advisory Boardno datano datano data
P. Willison
Member of Scientific Advisory Boardno datano datano data
Beth Stevens
Member of Scientific Advisory Boardno datano datano data

6.1yrs

Average Tenure

66yo

Average Age

Experienced Board: ANNX's board of directors are considered experienced (6.1 years average tenure).